top selling glp-1 drugs Receptor Agonist Shortage: Challenges and Solutions in Type 2 Diabetes Care 2025’s Breakthrough GLP-1 Obesity Treatments:

As of 28 October 2024, the UK Government's med watch database (MHRA) received over 7,000 reports of gastrointestinal side effects linked to GLP-1RAs, with some resulting in hospitalization

Effects on Non-Alcoholic Fatty Liver Disease Non-alcoholic fatty liver disease (NAFLD) is a metabolic stress liver injury closely related to IR and genetic variations

Its a small thing, but one we scarcely see outside of the telehealth space

GLP-1 therapy addresses hyperglycaemia whilst potentially contributing to blood pressure reduction, simplifying the therapeutic regimen

Compounders have already sued to delay the date when they are prohibited from compounding semaglutide, too

Nat Med 2022;28(10):20832091